Document is current
Any future updates will be listed below
-
Authors
,
Trifirò, Gianluca
Crisafulli, Salvatore
Andò, Giuseppe
Racagni, Giorgio
Drago, Filippo
- License Information
-
More Information
Article History
First Online: 17 April 2020
Compliance with Ethical Standards
:
: No sources of funding were used to prepare this commentary.
: G. Trifirò has served on advisory boards for Sandoz, Hospira, Sanofi, Biogen, Ipsen and Shire; is a consultant for Otsuka; is the principal investigator of observational studies funded by several pharmaceutical companies (e.g. Amgen, AstraZeneca, Daiichi Sankyo, and IBSA) to University of Messina; and is scientific coordinator of the Master’s program ‘Pharmacovigilance, pharmacoepidemiology and pharmacoeconomics: real-world data evaluations’ at University of Messina, which is partly funded by several pharmaceutical companies. G. Andò has received personal fees and non-financial support from Bayer, Pfizer, Bristol Myers Squibb and Boehringer Ingelheim; personal fees from Daiichi Sankyo, Menarini, AstraZeneca, Chiesi and Biosensors; and non-financial support from Terumo, all outside the submitted work. Salvatore Crisafulli, Giorgio Racagni and Filippo Drago have no conflicts of interest that are directly relevant to the content of this commentary.
Free to read: This content has been made available to all.
